Logo image of CTOR

CITIUS ONCOLOGY INC (CTOR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTOR - US17331Y1091 - Common Stock

1.12 USD
-0.01 (-0.88%)
Last: 11/24/2025, 8:00:00 PM
1.13 USD
+0.01 (+0.89%)
After Hours: 11/24/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CTOR. CTOR was compared to 533 industry peers in the Biotechnology industry. CTOR has a bad profitability rating. Also its financial health evaluation is rather negative. CTOR is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTOR had negative earnings in the past year.
In the past year CTOR had a positive cash flow from operations.
CTOR Yearly Net Income VS EBIT VS OCF VS FCFCTOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

CTOR's Return On Assets of -45.54% is in line compared to the rest of the industry. CTOR outperforms 54.03% of its industry peers.
CTOR has a worse Return On Equity (-128.91%) than 60.98% of its industry peers.
Industry RankSector Rank
ROA -45.54%
ROE -128.91%
ROIC N/A
ROA(3y)-20.16%
ROA(5y)N/A
ROE(3y)-21.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTOR Yearly ROA, ROE, ROICCTOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

CTOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTOR Yearly Profit, Operating, Gross MarginsCTOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

CTOR has less shares outstanding than it did 1 year ago.
CTOR has a worse debt/assets ratio than last year.
CTOR Yearly Shares OutstandingCTOR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
CTOR Yearly Total Debt VS Total AssetsCTOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

CTOR has an Altman-Z score of -1.80. This is a bad value and indicates that CTOR is not financially healthy and even has some risk of bankruptcy.
CTOR has a Altman-Z score (-1.80) which is comparable to the rest of the industry.
CTOR has a debt to FCF ratio of 5.53. This is a neutral value as CTOR would need 5.53 years to pay back of all of its debts.
CTOR's Debt to FCF ratio of 5.53 is amongst the best of the industry. CTOR outperforms 91.56% of its industry peers.
CTOR has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CTOR (0.12) is worse than 63.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 5.53
Altman-Z -1.8
ROIC/WACCN/A
WACCN/A
CTOR Yearly LT Debt VS Equity VS FCFCTOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

CTOR has a Current Ratio of 0.35. This is a bad value and indicates that CTOR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.35, CTOR is not doing good in the industry: 93.81% of the companies in the same industry are doing better.
CTOR has a Quick Ratio of 0.35. This is a bad value and indicates that CTOR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CTOR (0.02) is worse than 97.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.02
CTOR Yearly Current Assets VS Current LiabilitesCTOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

CTOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.51%.
EPS 1Y (TTM)-74.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-297.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 55.21% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-57.53%
EPS Next 2Y47.11%
EPS Next 3Y55.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTOR Yearly Revenue VS EstimatesCTOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 20M 40M 60M 80M 100M
CTOR Yearly EPS VS EstimatesCTOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 0.2 -0.2 0.4 -0.4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CTOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 21.96, the valuation of CTOR can be described as rather expensive.
Based on the Price/Forward Earnings ratio, CTOR is valued cheaply inside the industry as 92.50% of the companies are valued more expensively.
CTOR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.45, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 21.96
CTOR Price Earnings VS Forward Price EarningsCTOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

CTOR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CTOR is cheaper than 90.81% of the companies in the same industry.
Industry RankSector Rank
P/FCF 135.99
EV/EBITDA N/A
CTOR Per share dataCTOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as CTOR's earnings are expected to grow with 55.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.11%
EPS Next 3Y55.21%

More info and screens

0

5. Dividend

5.1 Amount

CTOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS ONCOLOGY INC

NASDAQ:CTOR (11/24/2025, 8:00:00 PM)

After market: 1.13 +0.01 (+0.89%)

1.12

-0.01 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)12-25 2025-12-25
Inst Owners0.68%
Inst Owner Change3651.22%
Ins Owners0.03%
Ins Owner Change8.37%
Market Cap93.53M
Revenue(TTM)N/A
Net Income(TTM)-41.76M
Analysts82.86
Price Target6.12 (446.43%)
Short Float %2.66%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.94%
Min EPS beat(2)-19.83%
Max EPS beat(2)47.71%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 21.96
P/S N/A
P/FCF 135.99
P/OCF 135.99
P/B 2.89
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.05
Fwd EY4.55%
FCF(TTM)0.01
FCFY0.74%
OCF(TTM)0.01
OCFY0.74%
SpS0
BVpS0.39
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.54%
ROE -128.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.16%
ROA(5y)N/A
ROE(3y)-21.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 5.53
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.02
Altman-Z -1.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-297.63%
EPS Next Y-57.53%
EPS Next 2Y47.11%
EPS Next 3Y55.21%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-69.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1152.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1152.71%
OCF growth 3YN/A
OCF growth 5YN/A

CITIUS ONCOLOGY INC / CTOR FAQ

What is the ChartMill fundamental rating of CITIUS ONCOLOGY INC (CTOR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTOR.


Can you provide the valuation status for CITIUS ONCOLOGY INC?

ChartMill assigns a valuation rating of 4 / 10 to CITIUS ONCOLOGY INC (CTOR). This can be considered as Fairly Valued.


How profitable is CITIUS ONCOLOGY INC (CTOR) stock?

CITIUS ONCOLOGY INC (CTOR) has a profitability rating of 1 / 10.